Lantheus cautioned that TAUKLARIFY’s safety and effectiveness have not been established for other brain diseases, and reports surfaced that Curium planned an up-to-$8 billion acquisition of Lantheus.

The TAUKLARIFY approval adds to the investment narrative in two ways: it diversifies the portfolio but leaves pricing and rollout risks, making its impact dependent on investors’ focus on diversification versus risk.

Approval was based on two blinded studies with more than 500 participants across three trials, including individuals with mild cognitive impairment, mild Alzheimer’s dementia, and cognitively unimpaired controls.

TAUKLARIFY is indicated to evaluate abnormal tau accumulation in cognitively impaired patients and can aid physicians in assessing potential Alzheimer's disease.

Lantheus Holdings won FDA approval for TAUKLARIFY, a tau PET imaging agent, expanding its molecular imaging portfolio for Alzheimer's diagnostics.

Safety data from two clinical trials involving over 1,700 participants showed adverse reactions in fewer than 1% of subjects, supporting the approval.

The tau-imaging market is dominated by Eli Lilly’s Tauvid, with total market potential under $100 million annually and TAUKLARIFY sales projected by some analysts to be under $50 million by 2030.

The approval complements Lantheus’s broader Alzheimer's imaging franchise, which now includes label expansions for Neuraceq and the late-stage radiodiagnostic MK-6240, positioning the company to meet rising demand for earlier diagnosis.

In studies with 279 and 338 subjects, TAUKLARIFY demonstrated strong diagnostic performance, with high inter-reader agreement across trials.

Lantheus stock traded slightly lower, around $101, at the time of publication.

Execution risk remains due to label limitations and the challenge of a broad rollout, amid competition from GE HealthCare and Eli Lilly.

TAUKLARIFY is designed to identify tau neurofibrillary tangles, but its safety and effectiveness for non-Alzheimer’s tauopathies remain unestablished.